Molecular Templates to Participate in Upcoming Virtual Investor Conferences

AUSTIN, Texas, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that it will present and participate in 1-on-1 investor meetings at the Cowen 41st Annual Health Care Conference, the Barclays Global Healthcare Conference and the Oppenheimer 31st Annual Healthcare Conference.

Cowen 41st Annual Health Care Conference
Conference Dates: March 1-4
Presentation Date and Time: Thursday, March 4th at 11:10 AM ET
        
Barclays Global Healthcare Conference
Conference Dates: March 9-11
Presentation Date and Time: Wednesday, March 10th at 3:00 PM ET

Oppenheimer 31st Annual Healthcare Conference
Conference Dates: March 16-17
Presentation Date and Time: Wednesday, March 17th at 11:20 AM ET         

Live webcasts of these presentations will be available in the “News and Events” section of the MTEM website at www.mtem.com. Additionally, replays of the webcasts will be available on the corporate website following the conferences. 

About Molecular Templates  
Molecular Templates is a clinical-stage company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.

Investor Contact:
Adam Cutler
Chief Financial Officer
adam.cutler@mtem.com
862-204-4006

Source: Molecular Templates, Inc.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.